Biophotonic imaging of ffLuc+ Daudi cells before and after adoptive T-cell therapy. Scatter graphs of tumor flux versus time and pseudocolor images of selected mice (red lines) representing light intensity from ffLuc+ Daudi cells in the peritoneum of NOD/scid mice serially imaged in ventral position. On day 0, NOD/scid mice were given 5 × 106 ffLuc+ Daudi cells by intraperitoneal injection. (ffLuc+ Daudi in vitro ffLuc activity was 141 ± 8 CPM/cell (mean ± SD), compared with 0.05 CPM/cell background ffLuc activity in parental Daudi cells.) The mice with progressive disease, documented by 2 concurrent measurements demonstrating increase in tumor flux (measured on days 2 and 6), were among 4 treatment groups. The 5 mice from group A received no further cellular therapy. On day 7, the 5 mice in groups B, C, and D received 20 × 106 MP1-tetramer+CD19R+CD8+ T cells by intraperitoneal injection. Mice from group D received additional injections of 20 × 106 MP1-tetramer+CD19R+CD8+ effector T cells on days 9 and 12. On days 7, 9, 12, 21, 23, and 25, the mice in groups B and C received separate intraperitoneal injections of 5 × 106 thawed and γ-irradiated autologous hygromycin B-resistant T-APC that had been genetically modified with HyMP1-pMG (group B) or pMGP̂ac (group C) coding for HyMP1 and Hy genes, respectively. All mice received rhIL-2 (25 000 U/mouse) by separate intraperitoneal injection on days 7, 9, 12, 21, 23, and 25. Each mouse was imaged at the same relative time point after D-luciferin administration, which was within 19 minutes of injection. Data are presented as photon flux for a region of interest (ROI) encompassing the whole mouse. Similar data were obtained in repeated experiments (data not shown).
